Investigating the utility of COVID-19 antibody testing in end-stage renal disease patients receiving haemodialysis: a cohort study in the United Kingdom.

Olivia WickensRajkumar ChinnaduraiFahmida MannanFrida SvendsenMirza Yasar BaigChukwuma ChukwuIbrahim AliChristina SummersgillDawn EvansBerckley V AntoineJulie OxtonNathan MairsEmma FlanaganRobert OliverPhilip A KalraDimitrios Poulikakos

Published in: BMC nephrology (2021)

Serological testing in the HD population is a valuable tool to determine seroprevalence, monitor exposure, and guide improvements for infection prevention and control (IPC) measures to help prevent local outbreaks. This study revealed HD patients mount a humoral response detectable until at least 7 months after COVID-19 infection and provides hope of similar protection with the vaccines recently approved.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
coronavirus disease
immune response
sars cov
ejection fraction
newly diagnosed